agalsidase beta (Rx)

Brand and Other Names:Fabrazyme
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection, lyophilized powder for reconstitution

  • 5mg/vial
  • 35mg/vial

Fabry Disease

Indicated for confirmed Fabry disease

1 mg/kg IV q2Weeks  

Dosage Forms & Strengths

injection, lyophilized powder for reconstitution

  • 5mg/vial
  • 35mg/vial

Fabry Disease

Indicated for confirmed Fabry disease in adults and pediatric patients aged ≥2 years

<2 years: Safety and efficacy not established

≥2 years: 1 mg/kg IV q2Weeks  

Next:

Interactions

Interaction Checker

and agalsidase beta

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Adults

            • Upper respiratory tract infection (53%)
            • Chills (49%)
            • Pyrexia (39%)
            • Headache (39%)
            • Cough (33%)
            • Paresthesia 31%)
            • Fatigue (24%)
            • Peripheral edema (21%)
            • Dizziness (21%)
            • Rash (20%)
            • Pain in extremity (19%)
            • Myalgia (18%)
            • Lower respiratory tract infection (18%)
            • Pain (16%)
            • Back pain (16%)
            • Hypertension (14%)

            Pediatric patients

            • Headache (>20%)
            • Abdominal pain (>20%)
            • Pharyngitis (>20%)
            • Fever (>20%)
            • Nausea (>20%)
            • Vomiting (>20%)
            • Rhinitis (>20%)
            • Diarrhea (>20%)
            • Arthralgia (>20%)
            • Dizziness (>20%)

            1-10%

            Adults

            • Pruritus (10%)
            • Tachycardia (9%)
            • Excoriation (9%)
            • Increased blood creatinine (9%)
            • Tinnitus (8%)
            • Dyspnea (8%)
            • Fall (6%)
            • Burning sensation (6%)
            • Anxiety (6%)
            • Depression (6%)
            • Wheezing (6%)
            • Hypoacusis (5%)
            • Chest discomfort (5%)
            • Fungal infection (5%)
            • Viral infection (5%)
            • Hot flush (5%)

            Postmarketing Reports

            Cardiovascular: Cardiorespiratory arrest, cardiac failure, myocardial infarction, palpitations

            Infections: Sepsis and pneumonia

            Infusion-associated reactions: Anaphylaxis, localized angioedema (eg, auricular swelling, eye swelling, dysphagia, lip swelling, edema, pharyngeal edema, face swelling, swollen tongue), and bronchospasm

            General: Hyperhidrosis, asthenia, infusion site reaction

            Lymphatic: Lymphadenopathy

            Musculoskeletal: Arthralgia

            Nasopharyngeal: Rhinorrhea

            Neurologic: Cerebrovascular accident, hypoesthesia, oral hypoesthesia

            Ophthalmologic: Increased lacrimation

            Pulmonary: Respiratory failure, hypoxia

            Renal: Renal failure

            Dermatologic: Erythema

            Vascular: Leukocytoclastic vasculitis

            Previous
            Next:

            Warnings

            Contraindications

            None

            Cautions

            Anaphylaxis and hypersensitivity reactions

            • In clinical trials and postmarketing safety experience, anaphylactic or severe hypersensitivity reactions reported
            • Higher incidences of hypersensitivity reactions were observed in adults with persistent anti-Fabrazyme antibodies and with high antibody titer compared to that in antibody negative adults
            • Consider testing for IgE antibodies in patients who experienced suspected hypersensitivity reactions
            • Consider risks and benefits of continued treatment in patients with anti-Fabrazyme IgE antibodies
            • No marketed tests for antibodies; if testing is warranted, contact Genzyme Corporation at 1-800-745-4447
            • Patients who have had a positive skin test or have tested positive for Fabrazyme-specific IgE antibody have been rechallenged using a rechallenge protocol
            • Rechallenge under direct supervision of qualified personnel, with appropriate medical support measures readily available

            Infusion-associated reactions

            • Infusion-associated reactions, some severe, reported
            • Incidence was higher in patients positive for anti-Fabrazyme antibodies compared with those who were negative
            • Severe infusion-associated reactions included chills, vomiting, hypotension, and paresthesia
            • Other infusion-associated reactions included pyrexia, feeling hot or cold, dyspnea, nausea, flushing, headache, fatigue, pruritus, pain in extremity, hypertension, chest pain, throat tightness, abdominal pain, dizziness, tachycardia, nasal congestion, diarrhea, edema peripheral, myalgia, urticaria, bradycardia, and somnolence
            • Ensure appropriate medical support measures are readily available during administration
            • Closely monitor with history infusion-associated reactions
            • Advanced Fabry disease may compromise cardiac function, which may potentially increase risk of severe complications from infusion-associated reactions; closely monitor with compromised cardiac function
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            Registry available and monitors drug effects on pregnant women and their offspring

            For more information, visit www.registrynxt.com or call 1-800-745-4447, extension 15500

            Encourage patients to enroll for the registry

            Available data from postmarketing case reports and case series with use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes

            Animal data

            • Reproduction studies performed in rats at doses up to 68 times the human dose have revealed no evidence of effects on embryo-fetal development

            Lactation

            There are no data on the presence of agalsidase beta in either human or animal milk, the effects of the drug on the breastfed infant, or on milk production

            Developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition

            Encourage lactating women to enroll in the registry

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Recombinant alpha-galactosidase A, an enzyme (deficient in Fabry disease) involved in the metabolism of glycosphingolipids (eg, GL-3); corrects abnormal glycosphingolipid metabolism resulting in reduced accumulation of glycosphingolipids and improvement of associated clinical manifestations; reduces GL-3 deposition in capillary endothelium

            Absorption

            Peak plasma concentration: 0.6-29.7 mcg/mL (0.3-1 mg/kg-dose)

            Distribution

            Vd (steady-state): 81-330 mL/kg (0.3-1 mg/kg-dose)

            Elimination

            Half-life: 45-102 min (0.3-1 mg/kg-dose)

            Clearance: 0.8-4.6 mL/min/kg (0.3-1 mg/kg-dose)

            Previous
            Next:

            Administration

            IV Incompatibilities

            Do not in same IV line with other products

            IV Compatibilities

            0.9% NaCl

            IV Preparation

            Calculate dose based on patient’s body weight and select a combination of 35-mg and 5-mg vials

            Remove vials from refrigerator and allow them to reach room temperature before reconstituting (~30 min)

            Reconstitution

            • 35-mg vials: Reconstitute with 7.2 mL of sterile water for injection (SWI) (total extractable solution per vial is 7 mL)
            • 5-mg vials: Reconstitute with 1.1 mL of SWI (total extractable solution per vial is 1 mL)
            • Roll and tilt each vial gently to yield a 5 mg/mL clear, colorless solution
            • Visually inspect for particulate matter and discoloration; discard if there is particulate matter or discoloration
            • Discard any unused product
            • Avoid shaking or agitating this product; do not use filter needles during preparation

            Dilution

            • Further dilute reconstituted solution with 0.9% NaCl to a total volume based on patient weight
            • Slowly withdraw reconstituted solution to required dose volume and inject directly into 0.9% NaCl
            • Do not inject in airspace within infusion bag; discard any vial with unused reconstituted solution
            • Gently invert infusion bag to mix, avoiding vigorous shaking and agitation
            • Minimum total infusion volume based on patient’s weight
              • ≤35 kg: 50 mL
              • 35.1-70 kg: 100 mL
              • 70.1 to 100 kg: 250 mL
              • >100 kg: 500 mL

            IV Administration

            Administer as an IV infusion using an in-line low protein binding 0.2-micron filter

            Do not infuse in the same IV line with other products

            Appropriate medical support measures should be readily available

            Administer antipyretics before infusion

            Infusion rate

            • 0.25 mg/min (15 mg/hr) initially; may increase rate based on patient’s weight once tolerance to infusion is well established
            • >30 kg: Increase rate in increments of 0.05-0.08 mg/min (increments of 3-5 mg/hr) with each subsequent infusion; minimum infusion duration is 1.5 hr (based on tolerability)
            • <30 kg: Maximum infusion rate is 0.25 mg/min (15 mg/hr)
            • Slow infusion rate in event of an infusion-associated reaction

            Rechallenge procedure

            • Patients who have had a positive skin test or tested positive for anti-Fabrazyme IgE may be successfully rechallenged
            • Initial rechallenge administration should be a low dose at a lower infusion rate (eg, ½ the therapeutic dose [0.5 mg/kg] at 1/25 of initial standard rate [0.01 mg/min])
            • Once tolerated, may increase dose to 1 mg/kg and slowly titrate rate up (doubled q30min up to a maximum rate of 0.25 mg/min), as tolerated

            Storage

            Does not contain preservatives

            Unused vials

            • Single use only
            • Refrigerate at 2-8ºC (36-46ºF); do not use after expiration date on vial

            Reconstituted vials and diluted solutions

            • Use immediately
            • If immediate use is not possible, refrigerate at 2-8ºC (36-46ºF) for up to 24 hr
            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.